Synergistic therapy of breast cancer with Y90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocol

Academic Article


  • Background. Paclitaxel (Taxol) has demonstrated synergistic enhancement of radioimmunotherapy (RIT) of breast cancer with Y-90 labeled antibody ChL6, in the xenografted mouse model. To determine the optimal sequence and timing of RIT and Taxol for a prospective clinical trial, efficacy and dosimetry in mice, and dosimetry in patients receiving RlT alone, were examined. Materials and Methods. Mice bearing human breast cancer xenografts (HBT 3477) received i.v. Y-90-DOTA-peptide-ChL6 (260 μCi), and i.p. Taxol (300 or 600 μg) 72, 48, or 24 hours prior to RIT, or 6, 24, 48, or 72 hours after RIT. Results. Taxol after RIT resulted in cure, CR or PR of all mice (70/70 tumors) and demonstrated greater therapeutic enhancement (p = 0.001) than Taxol before RIT. Mice receiving 600 μg Taxol 48 hours after RlT achieved 88% cure (7/8 tumors). In mice, 57% and 42% of the radiation dose to tumor and marrow, respectively, was delivered from 48-336 hours after RIT; in patients receiving 90Y-DOTA-peptide-ChL6, the corresponding values were 56% and 22%. Conclusions. Taxol given approximately 48 hours after RIT provides coincident peak deposition of Taxol and Y-90 in tumor, and no Taxol in the marrow during the major radiation dose to marrow, resulting in therapeutic enhancement without observable additive toxicity. A clinical trial of low dose Taxol given after RIT to patients with metastatic breast cancer is planned.
  • Authors

    Pubmed Id

  • 21460676
  • Author List

  • DeNardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
  • Start Page

  • 4011
  • End Page

  • 4018
  • Volume

  • 18
  • Issue

  • 6 A